Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study

The Lancet

Volumn 375, Issue 9711, 2010, Pages 283-293

  Cannon, Christopher P ^a   Harrington, Robert A ^b   James, Stefan ^c   Ardissino, Diego ^d   Becker, Richard C ^b   Emanuelsson, Håkan ^e   Husted, Steen ^g   Katus, Hugo ^h   Keltai, Matyas ⁱ   Khurmi, Nardev S ^f   Kontny, Frederic ^j   Lewis, Basil S ^k   Steg, Philippe Gabriel ^l   Storey, Robert F ^m   Wojdyla, Daniel ^b   Wallentin, Lars ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

^d UNIVERSITY HOSPITAL OF PARMA   (Italy)

^e ASTRAZENECA R AND D   (Sweden)

^f ASTRAZENECA   (United Kingdom)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

^h UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁱ Hungarian Institute of Cardiology   (Hungary)

^j Volvat Medical Centre   (Norway)

^k Lady Davis Carmel Medical Centre   (Israel)

^l UNIVERSITÉ PARIS DESCARTES   (France)

^m UNIVERSITY OF SHEFFIELD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; PROTON PUMP INHIBITOR; TICAGRELOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HEART INFARCTION; HOSPITAL PATIENT; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; TREATMENT PLANNING;

EID: 74649085430     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)62191-7     Document Type: Article

References (35)

1. Anderson J.L., Adams C.D., Antman E.M., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 guidelines for the management of patients with unstable angina/non-st-elevation myocardial infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50 (2007) e1-e157
2. Antman E.M., Hand M., Armstrong P.W., et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 51 (2008) 210-247
3. Bassand J.P., Hamm C.W., Ardissino D., et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28 (2007) 1598-1660
4. Van de Werf F., Bax J., Betriu A., et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 29 (2008) 2909-2945
5. Gurbel P.A., Bliden K.P., Hiatt B.L., and O'Connor C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (2003) 2908-2913
6. Wiviott S.D., Trenk D., Frelinger A.L., et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116 (2007) 2923-2932
7. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
8. Alexander D., Ou F.S., Roe M.T., et al. Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association guidelines (CRUSADE). Am Heart J 156 (2008) 606-612
9. Storey R.F., Husted S., Harrington R.A., et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 50 (2007) 1852-1856
10. Husted S., Emanuelsson H., Heptinstall S., Sandset P.M., Wickens M., and Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 27 (2006) 1038-1047
11. Gurbel P.A., Bliden K.P., Butler K., et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120 (2009) 2577-2585
12. Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361 (2009) 1045-1057
13. James S., Akerblom A., Cannon C.P., et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 157 (2009) 599-605
14. Cutlip D.E., Windecker S., Mehran R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
15. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329 (1993) 673-682
16. Kushner F.G., Hand M., Smith Jr. S.C., et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 54 (2009) 2205-2241
17. Sabatine M.S., Cannon C.P., Gibson C.M., et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 294 (2005) 1224-1232
18. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., and Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
19. Sabatine M.S., Cannon C.P., Gibson C.M., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 (2005) 1179-1189
20. Chen Z.M., Jiang L.X., Chen Y.P., et al. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1607-1621
21. Mehta SR. CURRENT OASIS 7: a 2X2 factorial randomized trial of optimal clopidogrel and aspirin dosing in patients with ACS undergoing an early invasive strategy with intent for PCI. European Society of Cardiology Scientific Sessions; Barcelona, Spain; Aug 30, 2009.
22. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 2 (1988) 349-360
23. Boersma E. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 27 (2006) 779-788
24. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
25. Boersma E., Harrington R.A., Moliterno D.J., et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 359 (2002) 189-198
26. Eikelboom J.W., Anand S.S., Malmberg K., Weitz J.I., Ginsberg J.S., and Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 355 (2000) 1936-1942
27. Mehta S.R., Cannon C.P., Fox K.A., et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 293 (2005) 2908-2917
28. Yusuf S., Mehta S.R., Chrolavicius S., et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354 (2006) 1464-1476
29. Stone G.W., Witzenbichler B., Guagliumi G., et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358 (2008) 2218-2230
30. Husted S., and van Giezen J.J. Ticagrelor: the first reversibly binding oral P2Y receptor antagonist. Cardiovasc Ther 27 (2009) 259-274
31. Van Giezen J.J., Nilsson L., Berntsson P., et al. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost 7 (2009) 1556-1565
32. Björkman J.-A., Kirk I., and van Giezen J.J. AZD6140 inhibits adenosine uptake into erythrocytes and enhances coronary blood flow after local ischemia or intracoronary adenosine infusion. Circulation 116 suppl II (2007) II-28 (abstr).
33. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
34. Berger P.B., and Steinhubl S. Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: a US perspective. Circulation 106 (2002) 2284-2287
35. Kleiman N.S., Lincoff A.M., Flaker G.C., et al. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. Circulation 101 (2000) 751-757